Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present new data on minimal residual disease (MRD) negativity rates from the Phase 3 CARTITUDE-4 trial ...

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

Brad Axis Brain and Back Institute +1 (817) 502-7411 ... Visit us on social media: Facebook X LinkedIn YouTube ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat advanced solid tumors and chemotherapy-induced peripheral neuropathy ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 202 ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...